ArticleJournal of clinical laboratory analysis2025
Clinical Significance of Plasma and Peripheral Blood Mononuclear Cell EBV-DNA in Lymphoma.
Article in Journal of clinical laboratory analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epstein-Barr virus-associated inflammatory polyp of the proximal cervical trachea causing central airway obstruction: a case report.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpstein Barr virus (EBV) is a ubiquitous virus that establishes latent infection in the host and plays a critical role in the development and prognosis of lymphomas. The presence of EBV-DNA in peripheral blood is a widely used tumor marker. However, there is no consensus on the preferred blood compartment for EBV-DNA testing.
methodsWe retrospectively analyzed data from 256 lymphoma patients, including 21 with Hodgkin lymphoma, 96 with B-cell lymphoma, and 139 with T-cell or NK/T-cell lymphoma. Complete matched PBMC and plasma EBV-DNA datasets were available, allowing correlation analysis and assessment of their respective clinical significance.
resultsDetectable pretreatment EBV-DNA in either plasma or PBMCs was significantly associated with worse survival outcomes (p < 0.001), with the worst prognosis observed in patients positive in both compartments. Longitudinal monitoring demonstrated that patients with negative EBV-DNA or declining viral loads in PBMCs or plasma had significantly improved progression-free survival compared to those with persistent positivity or increasing copy numbers (p < 0.001). Notably, changes in plasma EBV-DNA levels showed higher accuracy than PBMC EBV-DNA in reflecting treatment response. Multivariate analysis identified PBMC EBV-DNA positivity as an independent prognostic factor for inferior OS (p = 0.031) and PFS (p = 0.003).
conclusionBoth plasma and PBMC EBV-DNA are valuable for prognostic evaluation in lymphoma patients. Plasma EBV-DNA demonstrates superior utility for monitoring treatment response, whereas PBMC EBV-DNA provides stronger prognostic information. Selection of the appropriate sample type should be tailored to the clinical context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.